Brought to you by 
Merck, Lundbeck terminate sleep drug license deal
21 Apr 2015
Executive Summary
Merck & Co. Inc. is licensing US rights to H. Lundbeck AS's (psychiatric and neurological drugs) sleep disorder treatment gaboxadol. The companies will complete ongoing Phase III trials jointly, Merck paying most of the costs.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Lundbeck terminate sleep drug license deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice